AS03-adjuvanted H7N9 inactivated influenza vaccine

The AS03-adjuvanted H7N9 inactivated influenza vaccine is a pandemic preparedness candidate developed to prevent infection with the H7N9 avian influenza virus. The vaccine consists of a monovalent inactivated influenza antigen derived from the A/Hong Kong/125/2017 (Yangtze River Delta lineage) strain, manufactured by Sanofi, combined with the AS03 adjuvant system (an oil-in-water emulsion) provided by GSK. The vaccine targets the hemagglutinin (HA) protein on the surface of the virus to induce protective antibody responses. Clinical development has been primarily sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), including Phase II trials (such as NCT03750305) evaluating its safety and immunogenicity when administered either sequentially or simultaneously with seasonal quadrivalent inactivated influenza vaccines (IIV4). These studies aim to establish optimal dosing and co-administration strategies for pandemic response scenarios.

Other names

Influenza Virus Quadrivalent Inactivated Vaccine-National Institute of Allergy and Infectious Diseases (NIAID)-avian influenzaAS03-adjuvanted A/H7N9 Inactivated Influenza VaccineMonovalent 2017 H7N9 inactivated influenza vaccineMonovalent2017 H7N9 inactivated influenza vaccineMonovalent-2017 H7N9 inactivated influenza vaccineA/Hong Kong/125/2017 (H7N9) vaccine